Vanda Pharmaceuticals (NASDAQ:VNDA) Coverage Initiated by Analysts at StockNews.com

Research analysts at StockNews.com began coverage on shares of Vanda Pharmaceuticals (NASDAQ:VNDA) in a report issued on Sunday. The firm set a “hold” rating on the biopharmaceutical company’s stock.

VNDA has been the subject of several other research reports. HC Wainwright started coverage on shares of Vanda Pharmaceuticals in a research report on Thursday, October 31st. They set a “buy” rating and a $18.00 price objective for the company. Cantor Fitzgerald raised their target price on shares of Vanda Pharmaceuticals from $11.00 to $13.00 and gave the stock an “overweight” rating in a report on Thursday, August 1st.

Vanda Pharmaceuticals Stock Performance

Shares of NASDAQ VNDA opened at $5.00 on Friday. Vanda Pharmaceuticals has a 1 year low of $3.32 and a 1 year high of $6.75. The firm has a market cap of $291.54 million, a P/E ratio of -17.86 and a beta of 0.77. The stock has a fifty day moving average price of $4.80 and a two-hundred day moving average price of $5.26.

Institutional Investors Weigh In On Vanda Pharmaceuticals

Large investors have recently made changes to their positions in the company. Nantahala Capital Management LLC grew its position in Vanda Pharmaceuticals by 57.3% during the 2nd quarter. Nantahala Capital Management LLC now owns 1,593,516 shares of the biopharmaceutical company’s stock worth $9,003,000 after purchasing an additional 580,265 shares in the last quarter. Profit Investment Management LLC boosted its position in shares of Vanda Pharmaceuticals by 159.3% in the second quarter. Profit Investment Management LLC now owns 571,324 shares of the biopharmaceutical company’s stock worth $3,228,000 after buying an additional 351,000 shares during the period. Dimensional Fund Advisors LP grew its holdings in shares of Vanda Pharmaceuticals by 17.0% during the second quarter. Dimensional Fund Advisors LP now owns 2,013,807 shares of the biopharmaceutical company’s stock valued at $11,379,000 after buying an additional 292,172 shares in the last quarter. Monaco Asset Management SAM acquired a new position in Vanda Pharmaceuticals during the second quarter valued at $1,090,000. Finally, Massachusetts Financial Services Co. MA purchased a new stake in Vanda Pharmaceuticals in the 3rd quarter worth about $864,000. Institutional investors and hedge funds own 88.14% of the company’s stock.

Vanda Pharmaceuticals Company Profile

Vanda Pharmaceuticals Inc, a biopharmaceutical company, focuses on the development and commercialization of therapies to address high unmet medical needs worldwide. The company’s marketed products include HETLIOZ to treat non-24-hour sleep-wake disorders; and Fanapt oral tablets for the treatment of schizophrenia.